NasdaqGS:DNLIBiotechs
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report
Denali Therapeutics earnings set the tone for investors
Denali Therapeutics (DNLI) reported second quarter 2026 revenue of US$3.6 million, with a net loss of US$127.55 million and basic loss per share from continuing operations of US$0.68.
See our latest analysis for Denali Therapeutics.
Denali Therapeutics shares currently trade at US$24.40, with a 90 day share price return of 34.73% and a year to date share price return of 49.97%. The 1 year total shareholder return of 64.64% contrasts with...